No Data
No Data
Express News | Shanghai Fosun Pharma - Total Capital Contribution of Henan Fujian Shall Be RMB10.00 Mln
Express News | Shanghai Fosun Pharma - Formation of Partnership
FOSUN PHARMA (02196) subsidiary FOSUN Pingyao plans to invest 4.9 million yuan to establish Henan Rehabilitation.
FOSUN PHARMA (02196) announced that on April 25, 2025, the company's controlling subsidiary FOSUN PINGYAO...
FOSUN PHARMA (600196.SH): The holding subsidiary has signed a licensing agreement.
On April 25, Gelonghui reported that FOSUN PHARMA (600196.SH) announced that on April 25, 2025, its controlling subsidiary HENLIUS signed a "License Agreement" with Alvogen Korea, granting Alvogen Korea exclusive commercialization rights (including but not limited to sales) in the licensed area (i.e., South Korea) and field (i.e., extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), metastatic colorectal cancer (mCRC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) indications).
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
FOSUN PHARMA: ANNUAL REPORT 2024